Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996084 · ClinicalTrials.gov registry record
MS PATHS Normative Sub-Study
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 246
- Enrollment target
NCT02996084: Completed study, sponsored by Biogen.
NCT02996084 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 246 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996084 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 246 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the normative range of brain volume and brain volume change in healthy control (HC) participants whose age, race, and gender distribution is approximately matched to the age, race, and gender distribution of patients with Multiple Sclerosis (MS) enrolled in Study 888MS001. The secondary objective is to use the results of the primary endpoint to ensure consistency of brain volume measurements across MS PATHS centers.
Primary Outcome
Measured by using magnetic resonance imaging (MRI) scans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2022-12-31 |
What the finished NCT02996084 record still lists
NCT02996084 is an observational study that tracks outcomes without assigning an intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02996084 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02996084 about?
NCT02996084 is a clinical study titled "MS PATHS Normative Sub-Study". The primary objective of this study is to determine the normative range of brain volume and brain volume change in healthy control (HC) participants whose age, race, and gender distribution is approximately matched to the age, race, and gender distribution of patients with Multiple Sclerosis (MS) en...
What is the current status of trial NCT02996084?
This trial is currently completed. The enrollment target is 246 participants. The study started on 2017-12-12. Estimated completion is 2022-12-31.
Who is sponsoring clinical trial NCT02996084?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI